首页> 美国卫生研究院文献>Molecular and Clinical Oncology >Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy
【2h】

Recurrence patterns in patients with high-grade glioma following temozolomide-based chemoradiotherapy

机译:替莫唑胺为基础的放化疗后高级别胶质瘤患者的复发模式

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

There is currently no consensus regarding the optimal radiation volume for high-grade glioma (HGG). The brain volume irradiated is associated with the extent of radiation neurotoxicity. When reducing the treatment volume, the risk of geographic tumor miss should be considered. In such cases, the recurrence patterns and, particularly, the rate of marginal tumor recurrence, are important indices for determining the optimal radiation volume. In the present study, a smaller-target delineation protocol with limited margins was adopted. The postoperative enhancing tumor and resection cavity were defined as gross tumor volume (GTV); 1 and 2 cm were added to the GTV to create clinical target volume (CTV1 and CTV2), which received 60 and 54 Gy, respectively. At a median follow-up of 14 months, 54 HGG patients developed tumor recurrence. The median overall and progression-free survival were 14 and 10.5 months, respectively. A total of 34 patients developed central recurrence, 8 presented with in-field recurrence, 2 developed marginal recurrence, 2 had distant recurrence and 11 patients developed cerebrospinal fluid dissemination, 2 of whom developed central recurrence, with 1 patient simultaneously developing marginal recurrence. Local recurrence (central and in-field) was found to be the main recurrence pattern. As the rate of marginal recurrence was low (<5%), it appears that the smaller irradiated volume in the present study was appropriate. However, clinical trials investigating limited irradiation volume are required to validate our findings.
机译:目前尚无关于高级别胶质瘤(HGG)的最佳放射量的共识。辐射的大脑体积与放射神经毒性程度有关。当减少治疗量时,应考虑发生肿瘤遗漏的风险。在这种情况下,复发模式,特别是边缘肿瘤的复发率,是确定最佳放射量的重要指标。在本研究中,采用了具有有限余量的较小目标轮廓描述协议。术后增强肿瘤和切除腔定义为总肿瘤体积(GTV);将1 cm和2 cm添加到GTV以创建临床目标体积(CTV1和CTV2),分别接收60 Gy和54 Gy。在中位随访14个月时,有54例HGG患者出现了肿瘤复发。中位总生存期和无进展生存期分别为14和10.5个月。共有34例患者发展为中心性复发,8例为野外复发,2例为边缘性复发,2例为远处复发,11例发生脑脊液弥散,其中2例为中心性复发,1例同时发展为边缘性复发。发现局部复发(中央和现场)是主要的复发方式。由于边缘复发率较低(<5%),因此本研究中较小的照射量似乎是适当的。但是,需要进行临床研究以限制辐射量,以验证我们的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号